Open-label study of pemetrexed alone for chemonaive patients and pre-treated patients with malignant pleural mesothelioma: Outcomes of the International Expanded Access Program (EAP)

Paul Taylor,J. von Pawel,B. Castagneto,G. Dark,M. Marangolo,R.J. van Klaveren,J. Van Meerbeeck,Susumu Adachi,J Blatter

Open-label study of pemetrexed alone for chemonaive patients and pre-treated patients with malignant pleural mesothelioma: Outcomes of the International Expanded Access Program (EAP)

2007

Paul Taylor
J. von Pawel
B. Castagneto
G. Dark
M. Marangolo
R.J. van Klaveren
J. Van Meerbeeck
Susumu Adachi
J Blatter

7709 Background: In a previous phase II study of chemonaive malignant pleural mesothelioma (MPM) patients (pts), single-agent pemetrexed (P) resulted in a 14.1% response rate (RR) and median surviv...

Keywords:

Pemetrexed
Mesothelioma
Intensive care medicine
Expanded access
Medicine
open label study
Phases of clinical research
pleural mesothelioma
Oncology
Internal medicine
Response rate (survey)
Pathology

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations